Exelixis has received U.S. FDA approval of Cabometyx in patients 12 years and older with previously treated radioactive iodine-refractory differentiated thyroid cancer.
- Approval ahead of PDUFA target date of Dec. 4, 2021
- Approval based on results from COSMIC-311 trial
- Co. says it’s prepared to fully support expanded indication immediately
- Exelixis shares up over 2% in extended trading
To view the source of this information, click
To contact the reporter on this story:
To contact the editor responsible for this story:
© 2021 Bloomberg L.P. All rights reserved. Used ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.